


Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



WORD OF WELCOME

The EBMT Lymphoma and Cellular Therapy and Immunobiology Working Parties are proud to announce their first joint Educational Meeting. It is an interactive hands-on meeting on transplant and cellular immunotherapy for lymphoma and novel indications, such as autoimmune diseases. The aim of this event is to provide not only cutting-edge expert knowledge first-hand, but also close network opportunities with opinion leaders in the field. Accordingly, the size of the meeting (held in an inspiring Jugendstil building) will be limited to allow workshop character, and an important cornerstone will be interactive case presentations by young investigators.

The event will be opened with separate Business Meetings of the two Working Parties, providing a unique opportunity for interested attendees to get insight to the “inner life” of the Working Parties, learn about their scientific work, and get involved in ongoing or future projects.

The main programme covers not only all aspects of cellular therapy of the most frequent (and also some rare) types of lymphomas and some autoimmune diseases, but also CART toxicity management and lymphoma pathophysiology. Presentations are given by experts with a focus on educational and pedagogic value. The programme is built to target a broad audience of trainees, nurses and early to mid-career practitioners.

The 2026 joint CTIWP/LWP educational course will welcome you in the International Academic Forum Heidelberg. Being home of the oldest university in Germany, Heidelberg stands for a long tradition of scientific excellence. Heidelberg is easy to reach by plane (Frankfurt International Airport) but also very conveniently by train from all Europe.

We are looking forward to seeing you in Heidelberg!

Yours sincerely,

Ali Bazarbachi — Lymphoma Working Party Chair


Jürgen Kuball — Cellular Therapy and Immunobiology Working Party Chair

Peter Dreger — Local Organiser

Anna Sureda — Lymphoma Working Party SPC Member

Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



Wednesday, 28 October 2026
(All times in CET)

12:00 – 14:00 Lymphoma Working Party Scientific Business Meeting (part I)

12:00 – 14:00 Cellular Therapy and Immunobiology Working Party Scientific Business Meeting

14:00 – 15:00 Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Scientific Business Meeting

15:00 – 17:00 Lymphoma Working Party Scientific Business Meeting (part II)

17:00 – 17:30 Coffee Break

17:45 – 18:30 Keynote Lecture

Chairs: Ali Bazarbachi (LB) & Jürgen Kuball (NL)

17:45 - 18:30 The future of cellular therapy in lymphoma

Anna Sureda (ES)

Thursday, 29 October 2026
(All times in CET)

08:00 – 08:05 Welcome and Opening Remarks

Ali Bazarbachi (LB), Jürgen Kuball (NL), Peter Dreger (DE)

08:05 – 09:35 Session I — Aggressive lymphomas

Chairs: Bertram Glass (DE) & Ali Bazarbachi (LB)

08:05 - 08:25 New classifiers: does it matter for treatment

Fabrice Jardin (FR)

08:25 - 08:45 Sequencing of cellular therapies in DLBCL (CAR, Bispes, auto, allo)

Bertram Glass (DE)

08:45 - 09:05 Burkitt Lymphoma: current management standards and role of cellular therapy

Lorenz Thurner (DE)

09:05 - 09:15 Case presentation: Multimodal treatment of EBV-positive post-transplant lymphoproliferative disease including Tabelecleucel after allogeneic hematopoietic cell transplantation

Kiavasch Farid (DE)

09:15 - 09:35 Case and Session Discussion

09:35 – 10:00 Coffee Break

10:00 – 11:30 Session II — Follicular lymphoma and Mantle cell lymphoma

Chairs: Simona Pagliuca (FR) & Peter Dreger (DE)

10:00 - 10:20 Sequencing of cellular therapies in FL (CAR, Bispes, auto, allo)

Luca Castagna (IT)

10:20 - 10:40 Mantle cell lymphoma : chemotherapy, targeted therapy, cellular therapy, which option and sequence)

Olivier Hermine (FR)
Christiane Pott (DE)

10:40 - 11:00 MRD in FL and MCL: implications for prognosis and pre-emptive intervention

11:00 - 11:10 Case presentation: Second-line brexucabtagene autoleucel for mantle cell lymphoma with rapid progression on frontline acalabrutinib-based therapy: complete metabolic response complicated by severe ICANS and concurrent embolic stroke


Fernando Gibrán-Nunes (BR)

11:10-11:30 Case and Session Discussion

For further information, please contact scientificprogramme@ebmt.org

Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



Thursday, 29 October 2026 - continued
(All times in CET)

11:30 – 12:30 Session III — New targets and microbiota

Chairs: Ana Alarcón (ES) & Alex Rampotas (UK)

11:30 - 11:50	New microbiota data on CAR T-cells	Hendrick Poeck (DE)
11:50 - 12:10	Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms	Alex Rampotas (UK)
12:10 - 12:20	Case presentation: Investigating the role of CAR-T cell Secretome and Extracellular Vesicles in B-Cell Aplasia	Besjana Xhahysa (IT)
12:20 - 12:30	Case and Session Discussion	

12:30 – 13:30 Lunch Break

13:30 – 15:30 Session IV — Management of CART and Autoimmune Landscape

This session is kindly supported through an Independent Educational Grant by AstraZeneca

Chairs: Jürgen Kuball (NL) & Chara Kyriakou (UK)

13:30 - 13:50	CAR T activity for autoimmune diseases across EBMT centres	Raffaella Greco (IT)
13:50 - 14:10	The landscape of immune monitoring in CAR-T cell therapy	Simona Pagliuca (FR)
14:10 - 14:30	CAR T and impact on Quality of Life	Anne Spanjaart (NL)
14:30 - 14:50	What we learn from Biological Insights from CAR-T Toxicity in Multiple Myeloma Patients	David Fandrei (DE)
14:50 - 15:00	Case presentation: Managing CPI and CAR-T in young patient with refractory primary mediastinal diffuse large B-cell lymphoma: a case of pericarditis	Ambra Fumagalli (IT)
15:00 - 15:30	Case and Session Discussion	

15:30 – 16:00 Coffee Break

16:00 – 17:30 Session V — CART outcome predictors and late effects


Chairs: Jürgen Kuball (NL) & Nicole Santoro (IT)

16:00 - 16:20	Prognostic Scores and outcome predictors (CAR-Hematotox, EASIX, ICAHT) in CART therapy and beyond	Ana Alarcón (ES)
16:20 - 16:40	Frailty and eligibility criteria in CAR T recipients	Nicole Santoro (IT)
16:40 - 17:00	Secondary malignancies from the EBMT registry	Isabel Sánchez-Ortega (ES)
17:00 - 17:10	Case presentation: CAR-T-induced persistent bone marrow aplasia requiring emergency haploidentical transplantation in TP53-mutated mantle cell lymphoma with spinal and cutaneous relapse	Roberto Bono (IT)
17:10 - 17:30	Case and Session Discussion	

For further information, please contact scientificprogramme@ebmt.org

Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



Friday, 30 October 2026
(All timing in CET)

08:00 – 09:30 Session VI — T-cell lymphoma

Chair: Gandhi Damaj (FR)

- 08:00 - 08:25 The role of autologous and allogeneic Transplantation in PTCL-NOS, nTFHL, ALCL
08:25 - 08:50 The role of autologous and allogeneic Transplantation in rare TCL (HSTL, ENKTL, EATL, MEITL, ATLL, CTCL)
08:50 - 09:00 Case presentation: Ruxolitinib-based strategies in monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL): sustained survival beyond 18 months despite multiple relapses
09:00 - 09:30 Case and Session Discussion

Norbert Schmitz (DE)
Eva Domingo (ES)
Jorge Illarramendi (FR)

09:30 – 10:00 Coffee Break

10:00 – 11:30 Session VII — Hodgkin lymphoma

Chairs: Ali Bazarbachi (LB) & Norbert Schmitz (DE)

- 10:00 - 10:20 Is auto-HCT needed in all RR cHL patients?
10:20 - 10:40 The role of allo-HCT in cHL in 2026
10:40 - 11:00 The role of CART Cells in RR HL
11:00 - 11:10 Case presentation: Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Hodgkin Lymphoma in Real-World Clinical Practice: A Single-Center Experience in Kazakhstan
11:10 - 11:30 Case and Session Discussion

Carmen Martínez (ES)
Ali Bazarbachi (LB)
Ana Carolina Caballero (ES)

Dana Sailaubekova (KZ)

11:30 – 11:45 Closing Remarks

Ali Bazarbachi (LB), Jürgen Kuball (NL), Peter Dreger (DE)

Leading antibody science for better futures.



genmab.com



©2026 Genmab A/S COM-US-UNB-0001107 08/2026

SCIENCE TO MEDICINE



**Driven by
Science**



**Cutting-Edge
Technologies**




**Innovation
Built In-House**



**Robust Clinical
Pipeline**



**Science
at Our Core**





We Aspire to Cure Cancer.

At Takeda, we are united by our aspiration to cure cancer, with inspiration from patients and innovation from everywhere. Drawing on decades of leadership in oncology, we work to develop innovative treatments that enhance

and extend the lives of people living with cancer. We are committed to ensuring global access to our medicines, while focusing our research and development efforts on advancing medicines for hematologic, gastrointestinal and thoracic cancers.



Learn more at [TakedaOncology.com](https://www.takedaoncology.com)

©2026 Takeda Pharmaceuticals U.S.A., Inc.



Better Health, Brighter Future

Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



Thanks to our Sponsors

Sponsored Lecture



Gold Partners



Silver Partners

